The "Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Merck and Pfizer have received a major boost to their immune-oncology alliance with a second FDA Breakthrough Therapy Designation for Bavencio, this time in combination with Pfizer’s Inlyta.

A potential U.S. launch of this Chinese biotech's new lung cancer drug - which bested Merck's blockbuster Keytruda - is a key ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a midstage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...

Angina Pectoris Drugs Market Size and ForecastThe global angina pectoris drugs market is poised for substantial growth over ...

Better-than-expected financial results in recent quarters have signaled an improved outlook, helping to sustain the rally.

Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...